RecruitingPhase 3NCT06887127

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

An Open-label, Long-term Extension Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of TLL-018 in Patients With Rheumatoid Arthritis

Sponsor

Hangzhou Highlightll Pharmaceutical Co., Ltd

Enrollment

350 participants

Start Date

Mar 10, 2025

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis

Summary

The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of TLL-018 in patients with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with TLL-018.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This is a long-term follow-up study for people who already participated in a previous rheumatoid arthritis (RA) trial of TLL-018 (an experimental drug). It continues to monitor participants' safety and how they respond to treatment over a longer period. **You may be eligible if...** - You completed the earlier TLL-018-301 clinical trial within the past 3 months - You are between 18 and 75 years old - You are willing to use reliable contraception for at least 90 days after your last dose (if applicable) **You may NOT be eligible if...** - You are pregnant or breastfeeding - You experienced certain serious side effects in the previous trial - You have developed new conditions that make continued treatment unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.